CN116790456A - Bovine origin A type Pasteurella multocida strain, vaccine and application - Google Patents
Bovine origin A type Pasteurella multocida strain, vaccine and application Download PDFInfo
- Publication number
- CN116790456A CN116790456A CN202211185443.3A CN202211185443A CN116790456A CN 116790456 A CN116790456 A CN 116790456A CN 202211185443 A CN202211185443 A CN 202211185443A CN 116790456 A CN116790456 A CN 116790456A
- Authority
- CN
- China
- Prior art keywords
- strain
- pasteurella multocida
- cross
- bovine
- type
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000606856 Pasteurella multocida Species 0.000 title claims abstract description 51
- 229940051027 pasteurella multocida Drugs 0.000 title claims abstract description 51
- 241000283690 Bos taurus Species 0.000 title claims abstract description 43
- 229960005486 vaccine Drugs 0.000 title claims abstract description 29
- 208000015181 infectious disease Diseases 0.000 claims abstract description 19
- 241001465754 Metazoa Species 0.000 claims abstract description 18
- 238000002649 immunization Methods 0.000 claims abstract description 16
- 230000003053 immunization Effects 0.000 claims abstract description 16
- 241000271566 Aves Species 0.000 claims abstract description 11
- 244000144977 poultry Species 0.000 claims abstract description 11
- 206010034107 Pasteurella infections Diseases 0.000 claims abstract description 10
- 241000283973 Oryctolagus cuniculus Species 0.000 claims abstract description 7
- 238000012224 gene deletion Methods 0.000 claims description 10
- 238000004321 preservation Methods 0.000 claims description 8
- 241000606860 Pasteurella Species 0.000 claims description 6
- 201000005115 pasteurellosis Diseases 0.000 claims description 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 3
- 230000009993 protective function Effects 0.000 claims 1
- 229940031551 inactivated vaccine Drugs 0.000 abstract description 41
- 241000699670 Mus sp. Species 0.000 abstract description 38
- 241000282898 Sus scrofa Species 0.000 abstract description 5
- 238000010172 mouse model Methods 0.000 abstract description 3
- 101150018621 cra gene Proteins 0.000 description 35
- 239000013612 plasmid Substances 0.000 description 18
- 230000008859 change Effects 0.000 description 15
- 210000004072 lung Anatomy 0.000 description 14
- 230000001580 bacterial effect Effects 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 238000010276 construction Methods 0.000 description 9
- 238000012408 PCR amplification Methods 0.000 description 8
- 231100000614 poison Toxicity 0.000 description 8
- 235000013594 poultry meat Nutrition 0.000 description 8
- 239000003440 toxic substance Substances 0.000 description 8
- 238000011144 upstream manufacturing Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 241001052560 Thallis Species 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 241000287828 Gallus gallus Species 0.000 description 5
- 235000013330 chicken meat Nutrition 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 238000012449 Kunming mouse Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 238000009631 Broth culture Methods 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 108700005075 Regulator Genes Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000003209 gene knockout Methods 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 231100000483 muscle toxicity Toxicity 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000008807 pathological lesion Effects 0.000 description 2
- 210000002976 pectoralis muscle Anatomy 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000032969 Hemorrhagic Septicemia Diseases 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000014645 Pasteurella hemorrhagic septicemia Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 101100340151 Wolinella succinogenes (strain ATCC 29543 / DSM 1740 / LMG 7466 / NCTC 11488 / FDC 602W) hydD gene Proteins 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001775 anti-pathogenic effect Effects 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000006860 carbon metabolism Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000005099 host tropism Effects 0.000 description 1
- 101150090028 hyaD gene Proteins 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 101150078797 luxS gene Proteins 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 101150062728 qseC gene Proteins 0.000 description 1
- 230000018612 quorum sensing Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 244000000023 zoonotic pathogen Species 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention discloses a bovine origin A type pasteurella multocida strain, a vaccine and application thereofcraGene-deleted Strain (delta)cra) The strain is preserved in China Center for Type Culture Collection (CCTCC) No. M20221451, and is further prepared into an inactivated vaccine for immunization, so that cross immune protection of mice and poultry against infection of different serotypes and different animal sources of Pasteurella multocida can be promoted. The invention can promote the crossing of animals with different serotypes and different animal sources of Pasteurella multocida infectionImmune protection, the mouse model has 100% immune protection to infection of bovine-derived type A, B-derived type and swine-derived type A Pm, and the immune protection rate to bovine-derived type F, avian-derived type A and rabbit-derived type A Pm respectively reaches 70%, 90% and 80%; the immune protection rate of the poultry model against avian source A type Pasteurella multocida infection reaches 100 percent.
Description
Technical Field
The invention relates to the technical field of genetic engineering, in particular to a bovine origin A type Pasteurella multocida strain with cra gene deletion, a vaccine and application.
Background
Pasteurella multocida (Pasteurella multocida, pm) is a zoonotic pathogen that colonizes the upper respiratory tract of healthy animals as a symbiotic bacteria. Under various stress environmental conditions (such as long-distance transportation, environmental change, immunity reduction and the like), pm is greatly proliferated and spread to the lower respiratory tract to enter the lung or invade other parts through blood circulation, so that diseases such as pneumonia, hemorrhagic septicemia and the like are caused, animals die seriously, pm infects people, and symptoms such as shock, meningitis and the like can be caused.
Pm can be classified into A, B, D, E, F five capsular serotypes according to differences in capsular antigen, and 1-16 LPS serotypes according to differences in Lipopolysaccharide (LPS) antigen components. The common vaccine may only have protection effect on the infection of strains of the same animal source or the same serotype, and the cross protection among the different serotypes of the pasteurellosis bacillus is weak, while the existing commercial vaccine only has protection effect on the infection of homotypic Pm, which brings great challenges to the prevention and control of the pasteurellosis bacillus. Thus, the development of a vaccine against pasteurellosis is particularly important.
The early-stage research in the laboratory discovers that the deletion of quorum sensing regulatory genes qseC and luxS and a gene hyaD related to capsule synthesis endows the strain with cross protection property, and the effect of cra serving as a transcription regulatory gene for regulating carbon nutrition metabolism on the aspects of carbon metabolic process, virulence effect, immune protection and the like of the Pasteurella multocida is unknown.
Disclosure of Invention
In view of the above-mentioned shortcomings of the prior art, it is an object of the present invention to provide a strain of pasteurella multocida with a deletion of the cra gene and further use it for immunization, promoting cross protection of animals against infection with pasteurella multocida of different serotypes and different animal origin.
In order to solve the technical problems, the technical scheme adopted by the invention is as follows:
a bovine origin A type Pasteurella multocida strain is a cra gene deletion strain of bovine origin A type Pasteurella multocida PmCQ2 strain, and is preserved in China Center for Type Culture Collection (CCTCC) with the preservation number of M20221451.
Further, in the cra gene deletion strain, the amino acid sequence of the cra gene deletion part is SEQ ID NO.1.
Further, the bovine-derived pasteurella multocida strain has a cross-immune protection function and has the ability to cross-species infect poultry.
The invention also provides a Pasteurella multocida vaccine which is prepared by adopting the bovine origin A-type Pasteurella multocida strain.
Further, there is provided the use of the pasteurella vaccine for vaccination to promote cross-immune protection of animals against infection with pasteurella multocida of different serotypes, different animal sources.
Further, the cross protection is cross immune protection against bovine-derived type a, type B, type F pasteurella multocida infection.
Further, the cross-protection is cross-immune protection against swine and rabbit origin pasteurella multocida infection.
Further, the cross-protection is cross-immune protection against avian pasteurella multocida of type a, superior to avian pasteurella multocida vaccines.
Compared with the prior art, the invention has the following beneficial effects:
1. the invention discovers that the bovine-derived A-type Pasteurella multocida with the cra gene deleted has excellent cross protection characteristics, can be used as candidate strains for the development of Pm broad-spectrum vaccines, and lays a foundation for the commercialized application of the general vaccine of the Pasteurella multocida; the vaccine prepared from the extract has wide application prospect.
2. The deletion of the gene causes the change of host tropism of the bovine strain, and when the gene is not deleted, the strain cannot infect birds, but the deletion of the gene can infect birds, thereby providing a direction for researching cross-species infection of the pasteurella multocida.
3. From the perspective of vaccine, after cra gene of bovine strain is deleted, the invention has good cross protection effect on fowl-origin, pig-origin, rabbit-origin and bovine-origin pasteurella multocida in a mouse model; particularly in a model of poultry, the vaccine prepared by the strain also has good cross protection for the infection of the poultry-derived pasteurella multocida, and is better than the vaccine prepared by the poultry-derived pasteurella multocida.
4. The cattle source A type Pasteurella multocida vaccine with the cra gene deletion can promote the cross protection of animals on infection of different serotypes and different animal sources Pasteurella multocida, including the cross protection of cattle source A type, B type, F type and pig source, poultry source and rabbit source A type Pasteurella multocida infection, wherein the delta cra inactivated vaccine has 100 percent of immune protection on cattle source A type, B type and pig source A type Pm, and the protection rate on cattle source F type, poultry source A type and rabbit source A type Pm respectively reaches 70 percent, 90 percent and 80 percent.
Drawings
FIG. 1 is a schematic representation of the construction of a knockout strain and the associated primer binding sites of the present invention;
FIG. 2 is a graph showing survival of the detoxified mice after immunization with the inactivated vaccine of the present invention; wherein A, counteracting toxic substances PmCQ1; B. counteracting toxic substances PmCQ2; c, counteracting toxic substances PmCQ4; D. counteracting toxic substances PmCQ5; e.pmb; F. counteracting toxic substances PmF; G. counteracting toxic substances Pmp; H. attack toxic materials PmQ; I. attack toxic materials PmR;
FIG. 3 is a view showing organ colonization according to the present invention; wherein, A, B, C, D, E, F, G, P, H, pmQ, I, pmR are all the same;
FIG. 4 is a graph showing HE staining of lung tissue infection in immunized mice according to the invention;
FIG. 5 is a plot of the change in serum IgG antibody levels of delta cra inactivated vaccine immunized mice according to the invention; wherein, A. Anti-PmCQ 1 antibody dynamic change, B. Anti-PmCQ 2 antibody dynamic change, C. Anti-PmCQ 4 antibody dynamic change, D. Anti-PmCQ 5 antibody dynamic change, E. Anti-PmB antibody dynamic change, F. Anti-PmF antibody dynamic change, G. Anti-Pmp antibody dynamic change, H. Anti-PmQ antibody dynamic change, I. Anti-PmR antibody dynamic change;
FIG. 6 is a graph showing the survival of the virus-combating avian Pasteurella multocida after the immunization of chickens with an inactivated vaccine according to the invention.
Detailed Description
In order to enable those skilled in the art to better understand the technical solution of the present invention, the present invention will be further described with reference to specific examples, but the embodiments of the present invention are not limited thereto.
1. Construction method of cra gene knockout strain delta cra of bovine-derived Pasteurella multocida PmCQ2 strain and vaccine preparation method
EXAMPLE 1 construction of Deltacra by homologous recombination
1. Material
1.1 Strain
The cattle source A type Pasteurella multocida PmCQ2 (A: L3) is separated from the lung of calf suffering from pneumonia in a certain cattle farm of Chongqing, and is temporarily stored in a refrigerator of minus 80 ℃ in a cattle epidemic prevention and control laboratory of animal medical college of the university of West south.
Plasmid pUC19oriKan used as gene knockout R The protein expression vector pET30a is constructed and stored in the laboratory, and temporarily stored in the laboratory. E.coli DH 5. Alpha. And E.coli BL21 (DE 3) competent cells were purchased from Bomaide Biotechnology Co.
1.2 primers
Relevant primers (table 1) were designed for the construction of the cra knockout strain of PmCQ2 strain and the construction of the anaplerotic strain using NCBI gene library, snapge and bioengineering ltd, and synthesized and purified by Shanghai.
TABLE 1 related primers required for construction of knockout strains
2. Method of
2.1 construction of knockout plasmid vector pUC19oriKanR
Homologous recombination knockout plasmid pUC19oriKan R The transformation work is mainly completed by a laboratory, and a Kan expression nucleus, a temperature sensitive plasmid and a Pasteurella replication initiation site are inserted between two restriction sites of the original pUC19 plasmid KpnI and EcoRI.
2.2 construction of recombinant plasmid pUC19oriKanR- Δcraup+Down
2.2.1 amplification, purification and ligation of the upstream and downstream homology arms of the cra Gene
(1) Amplification and purification of the upstream and downstream homology arms: primers 5'ARM-F/5' ARM-R and 3'ARM-F/3' ARM-R are used for amplifying an upstream homology arm and a downstream homology arm of the cra gene respectively, and a glue recovery kit (manufactured by Kangji Biotechnology Co., ltd.) is used for recovering the upstream homology arm and the downstream homology arm respectively.
(2) Upstream and downstream homology arm ligation: ligating the purified upstream and downstream homology arms of cra and recovering the upstream and downstream homology arms Δcra of cra up+down After measuring the DNA concentration, the DNA is preserved at-20 ℃.
2.2.2 recombinant plasmid pUC19oriKan R –Δcra up+down Acquisition of (a)
(1)pUC19oriKan R Extraction of homologous recombinant plasmids: plasmids were extracted according to the instructions of the plasmid purification kit (Kangji Biotechnology Co., ltd.) and the concentration was measured by an enzyme-labeled instrument and stored at-20 ℃.
(2) Double enzyme cutting pUC19oriKan R Plasmid: cleavage sites BamHI and HindIII; and (3) enzyme cutting: the enzyme is digested with BamHI at 30℃for 2h and then with HindIII at 37℃for 2h.
(3) Purification of the linear vector: the linearized vector after enzyme digestion is recovered according to the specification of a gel recovery kit (manufactured by Kangji Biotechnology Co., ltd.) and is stored at-20 ℃ after measuring the DNA concentration by an enzyme-labeled instrument.
(4) And (3) connection: by Exnase TM II ligase purified cra upstream and downstream homology arm Δcra up+down Fragment and digested pUC19oriKan R The linearized vector is ligated. The reaction procedure: the tube wall reagent was centrifuged briefly and incubated at 37℃for 30min, cooled in an ice-water mixture and stored at-20 ℃.
(5) Conversion of ligation products: the ligation product was transformed into E.coli DH 5. Alpha. Competent cells, and after 10min of resuscitation in a 30℃incubator, the cells were cultured for 2h on a shaking table at 30℃and 220r/min, and the bacterial solution was spread on LB plates containing 100. Mu.g/mL Amp, and cultured for 16h at 30 ℃.
(6) Screening of positive clones: several single clones on the plate were picked with a pipette, colony PCR amplification verification was performed, and positive clones were screened.
(7) Sequencing: the positive clones are picked, amplified and cultured, plasmids are extracted and sent to a worker for sequencing, and the universal primers M13-48 are adopted for sequencing.
2.3 Preparation of PmCQ2 competence
(1) Streaking and activating the frozen PmCQ2 bacterial liquid on a Ma Dingshi broth solid culture medium, and culturing the bacterial liquid in an inverted manner in a 37 ℃ incubator for 20 hours;
(2) 2-3 single colonies were picked up and cultured in 5mL Ma Dingshi broth medium at 37℃in a 220r/min incubator for 10h, transferred to a flask containing 100mL Ma Dingshi broth medium at 1% inoculum size and again cultured in a 220r/min incubator at 37℃to OD 600 After the culture is carried out, 0.2 to 0.4 percent of hyaluronidase is added for continuous culture until the OD 600 =1.0 to 1.2, ice bath for 30min;
(3) Transferring the bacterial liquid after ice bath into a 50mL centrifuge tube, centrifuging at 5,000r/min and 5min and 4 ℃ and collecting bacterial bodies;
(4) Adding 30mL of 10% pre-cooled glycerol to resuspend the thalli, centrifuging at 5,000r/min and 5min and 4 ℃ to keep the thalli;
(5) Repeating the step (4) twice;
(6) Finally, 2mL of 10% pre-cooling glycerol is added to resuspend the thalli, 100 mu L/tube split charging of the thalli liquid is carried out, and the thalli are preserved at the temperature of minus 80 ℃ for standby after quick freezing by liquid nitrogen.
2.4 recombinant plasmid pUC19oriKan R –Δcra up+down Electric conversion of PmCQ2
(1) Recombinant plasmid pUC19oriKan R –Δcra up+down And PmCQ2 competent cells were thawed in an ice-water mixture;
(2) Transferring 10 mu L of recombinant plasmid into PmCQ2 competent cells, and uniformly mixing the light elastic tube walls;
(3) Transferring the mixed solution into a precooled electric shock cup, and carrying out electric shock for 5ms conversion under the conditions of voltage 2,500V and resistance 500 omega;
(4) Transferring the mixed solution to 900 mu L of Ma Dingshi broth containing 10% fetal bovine serum after electric shock is over, standing for resuscitation at 30 ℃ for 10min, and shake culturing at 30 ℃ for 3h at 220 r/min;
(5) After centrifugation of the mixture at 5,000r/min for 5min, 100. Mu.L of the supernatant was retained for resuspension of the cells, which were then plated on Martin plates containing 50. Mu.g/mL Kan resistance and incubated at 30 ℃.
The construction of the knockout strain and the associated primer binding sites are shown in FIG. 1.
2.5 screening of Gene-deleted Strain Δcra
(1) Picking single colony growing on the 2.4 plate, and carrying out PCR amplification by using pUC19-F/pUC19-R primer to ensure that the recombinant plasmid is transferred into PmCQ2 competent cells;
(2) After verifying that the recombinant plasmid is successfully transferred into the PmCQ2 competent cells, respectively streaking bacterial liquid on a Ma Dingshi broth solid medium containing 50 mug/mL Kan resistance, and culturing at 30 ℃ for 24 hours to enable the recombinant plasmid insert to exchange with the PmCQ2 genome;
(3) Selecting single colony growing on the culture medium (2), performing PCR amplification by using mcra-F/mcra-R primer, screening single colony with short band compared with wild PmCQ2 genome (namely target genes cra and delta cra) up+down Exchange has occurred);
(5) Single colony with genome exchanged verified by PCR amplification is selected and diluted in normal saline, the diluted colony is coated in a martin-free culture medium, and after the culture for 24 hours at 30 ℃, the PCR amplification is carried out again by using mcra-F/mcra-R primer until the condition that the screening nucleic acid gel electrophoresis shows only short band compared with PmCQ2 (namely delta cra up+down Complete exchange with cra occurs);
(6) Elimination of resistance: by utilizing the characteristics of a temperature-sensitive knockout vector (no replication at 42 ℃), single colonies with complete genome exchange are diluted by normal saline and then spread on Ma Dingshi broth agar culture medium without Kan resistance, cultured at 42 ℃ for 24h, PCR amplification is carried out by pUC19-F/pUC19-R until single colonies with the pair of primers not amplified out a band (namely plasmid loss) are screened out, the colonies are picked and streaked on Ma Dingping plates with Kan resistance, and sterile colony growth is carried out after culturing at 30 ℃ for 24 hours, so that the elimination of Kan resistance is confirmed.
In the cra gene deletion strain, the amino acid sequence of the cra gene deletion part is SEQ ID NO.1.
The cra gene deletion strain of the bovine-derived A-type Pasteurella multocida PmCQ2 strain is preserved in China center for type culture collection, and the preservation number is CCTCC NO: M20221451.
2.6 verification of genetic stability of Gene-deleted Strain Δcra
The knocked-out strain is continuously passaged for 30 times in vitro, then is subjected to PCR amplification verification by using a plurality of pairs of primers, then bacterial liquid is subjected to intraperitoneal toxicity attack to infect mice, lung homogenate is collected, streaks are carried out on a Ma Dingshi broth culture medium, a plurality of single colonies are picked, and PCR amplification is performed by using a plurality of pairs of primers, so that the stable inheritance of delta cra in vivo and in vitro is ensured.
EXAMPLE 2 preparation of vaccine for PmCQ2 strain cra Gene-deleted Strain of bovine-derived Pasteurella multocida
1. Raw materials
1.1 Strain
The cattle source A type Pasteurella multocida PmCQ2, the cattle source A type Pasteurella multocida PmCQ1 (A: L3), the PmCQ4 (A: L3) and the PmCQ5 (A: L3) are separated from calf nasal swabs of a certain farm in Chongqing, the cattle source B type Pasteurella multocida PmB (B: L2, CVCC 470) and the pig source A type Pasteurella multocida Pmp (A: L1, CVCC 1662) are purchased from China veterinary microbiological strain preservation and management center, the cattle source F type Pasteurella multocida PmF (F: L3) is separated from lung of a calf in a certain farm in Mitsu, the poultry source A type Pasteurella multocida PmQ (A: L1) is separated from rabbit liver of a certain farm in Chongqing. All the strains are temporarily stored in a refrigerator at-80 ℃ in a beef cattle epidemic prevention and control research laboratory of the university of southwest animal medical college.
1.2 animals
Female Kunming mice (18-22 g), chicks (ROSS 308,7 days old).
2. Preparation of inactivated vaccine
(1) The PmCQ2 cultured to the logarithmic growth phase and the Deltacra seed solution screened in example 1 are respectively transferred into a triangular flask according to the proportion of 1:100 for expansion culture, and bacterial liquid is centrifugally concentrated at 13,000r/min and 20min after pure test and dilution counting.
(2) Re-suspending the thalli with a proper amount of culture solution, adding formaldehyde solution with the final concentration of 0.15 percent into an incubator at 37 ℃ for inactivation for 24 hours, and carrying out vortex oscillation once every 4-6 hours;
(3) Mixing the inactivated bacterial liquid and PBS with 15AVG mineral oil adjuvant at a ratio of 4:1, and making into PBS emulsifier and 5.0X10 9 CFU/mL delta cra inactivated vaccine and PmCQ2 inactivated vaccine.
(4) And (3) culturing the inactivated Miao Tubu on a Ma Dingshi broth culture medium for 24 hours at a temperature of 37 ℃ in an incubator, detecting whether viable bacteria exist, and simultaneously inoculating the PmCQ2 inactivated vaccine, the Deltacra inactivated vaccine and the PBS emulsifier under the back skin of 6 mice respectively, performing vaccine safety evaluation, and storing at the temperature of 4 ℃ after the vaccine safety detection.
2. Determination and evaluation of cross-protection of cra Gene-deleted Strain Δcra
One mouse model
1. Cross-protective assay of Δcra inactivated vaccine in mice
(1) Immunization procedure: 270 female Kunming mice were randomly divided into 27 groups (n=10), the back of the mice was subcutaneously multi-vaccinated, while PBS emulsifier was injected as a control, boosted once after 14d prime, and the immunization procedure and challenge strains were as shown in Table 2:
TABLE 2 immunization procedure and detoxification
(2) Challenge of counteracting toxic substances: and after 21d of first time, the muscle toxicity attack detection and inactivation vaccine cross protection effect. The amount of the antidote is 3.8X10 respectively 7 CFU PmCQ1(LD 50 ＝3.8×10 2 CFU)、4.8×10 7 CFU PmCQ2(LD 50 ＝3.4×10 3 CFU)、4.2×10 7 CFU PmCQ4(LD 50 ＝2.1×10 3 CFU)、4.5×10 7 CFU PmCQ5(LD 50 ＝4.5×10 3 CFU)、1.0×10 7 CFU PmB (LD 50 ＝5.0×10 3 CFU)、6.5×10 8 CFU PmF(LD 50 ＝1.0×10 8 CFU)、10CFU PmQ(LD 50 ≈1CFU)、 10CFU PmP(LD 50 ≈1CFU)、2.0×10 6 CFU PmR(LD50＝1.0×10 4 CFU), 2 times per day after challenge, record the clinical symptoms of mice, euthanize when dying, record the number of mice dead, and record for 1 week continuously.
2. Determination of toxicity counteracting, lung colonisation and pathological injury after immunization
162 female Kunming mice were randomly divided into 27 groups (n=6), 9 groups of Δcra inactivated vaccine, pmCQ2 inactivated vaccine and control group were each provided, and the mice were subjected to subcutaneous multipoint immunization on the backs and challenged after 21d of priming. After 12h of infection, the mice are euthanized, the lungs, livers and spleens of the mice are collected, weighed, homogenized, diluted and plated, and the bacterial content of each organ is calculated; lungs of three mice in each group were randomly collected until 4% paraformaldehyde was immobilized, and three groups (Δcra inactivated vaccine, pmCQ2 inactivated vaccine, and control group) were simultaneously set to collect lungs at the same time point, and after 4% paraformaldehyde immobilization, the lungs were sent to the inside organism company to make pathological sections.
(II) chick model
1. Cross-protective assay of Δcra inactivated vaccine in chickens
(1) Immunization procedure: the 40 chicks (ROSS 308,7 days old) were randomly divided into 4 groups (n=10), the chick pectoral muscles were vaccinated with Δcra inactivated vaccine, pmQ inactivated vaccine and PmCQ2 inactivated vaccine, respectively, and PBS emulsifier was injected as a control, and were boosted once after 14d of priming, and the immunization procedure was as in table 2.
(2) Challenge of counteracting toxic substances: and after 21 days of first prevention, detecting the cross protection effect of the inactivated vaccine by using 100CFU PmQ for chest muscle toxicity attack. After challenge, the chickens were observed 2 times daily, and the clinical symptoms and death time of the chickens were recorded for 1 week.
(III) analysis of results
1. Safety inspection of inactivated vaccine
The sterilization test is carried out after the inactivation of delta cra and PmCQ2 formaldehyde and the emulsification of the adjuvant, and the result shows that the bacteria liquid after the treatment is coated on the MD plate and no mixed bacteria grow out, thus proving that the sterilization test of the inactivated vaccine is qualified; after the mice are respectively inoculated with the inactivated vaccine subcutaneously, no obvious tumor is generated, the mental state of the mice is good, and the vaccine safety is proved to be good.
2. Results of cross protection test of inactivated vaccine in mice
To evaluate the cross protection characteristics of the Δcra strain, the Δcra inactivated vaccine had 100% immune protection rate against bovine-derived type a (CQ 1, CQ2, CQ4, CQ5, and CQ 5) (fig. 2A-D), bovine-derived type B (fig. 2E), and porcine-derived type a Pm (fig. 2G), and 70%, 90%, 80% (fig. 2F, h, i), respectively, for the protection rate against bovine-derived type F, avian-derived type a, and rabbit-derived type a Pm after immunization of 21D against muscle challenge PmCQ1, pmCQ2, pmCQ4, pmCQ5, and PmB, pmF, pmP, pmQ, pmR against Kunming mice, and for one week, as shown in fig. 2; the PmCQ2 inactivated vaccine has more than 70% of immune protection rate to bovine-derived A-type Pm (shown in figures 2A-D), and almost no cross protection to bovine-derived B-type, F-type and other animal-derived Pm (shown in figures 2E-I). The results show that the Deltacra strain has good cross immune protection characteristics.
3. After the inactivated vaccine is immunized, the organ colonization result of the infected mice
To evaluate the resistance of Δcra-and PmCQ 2-inactivated vaccine-immunized mice to pathogenic bacterial infection, pmCQ1, pmCQ2, pmCQ4, pmCQ5, pmB, pmF, pmP, pmQ, pmR were infected respectively after the inactivated vaccine immunization for 21d, lung, liver, spleen organs of the mice 12h after infection were collected, and diluted plating counts were performed after tissue homogenization. The results show that the mice immunized by the delta cra inactivated vaccine infected by each strain have almost no colonization of various organs (figures 3A-I) and can rapidly clear bacteria in the body; the mice immunized with the PmCQ2 inactivated vaccine have a certain number of colonization amounts of all organs after being infected, wherein the colonization amounts of the bovine-derived type A Pasteurella multocida (PmCQ 1, pmCQ2, pmCQ4 and PmCQ 5) in all the organs are obviously lower than those of the control group (figures 3A-D), which indicates that the mice immunized with the PmCQ2 inactivated vaccine have a certain clearance capability on the infection of the bovine-derived type A Pasteurella multocida. The above results indicate that mice immunized with Δcra inactivated vaccine have extremely strong resistance to infection with other strains, while mice immunized with PmCQ2 strain inactivated vaccine have a certain clearance ability only against infection with bovine-derived pasteurella multocida a, which also verifies the cross-protection properties exhibited in fig. 3.
4. Results of lung pathological injury of infected mice after immunization with inactivated vaccine
To further evaluate the anti-pathogenic bacterial infection ability of Δcra-and PmCQ 2-inactivated vaccine-immunized mice, the mice were infected with PmCQ1, pmCQ2, pmCQ4, pmCQ5, pmB, pmF, pmP, pmQ, pmR, respectively, after 21d immunization of the inactivated vaccine, lungs of the mice 12H after the collection were fixed with 4% paraformaldehyde, and H & E-stained. The results show that the lung pathological lesions are lighter after the Δcra inactivated vaccine immunized mice are infected, almost no change of cell structure or inflammatory cell infiltration is caused, but the PmCQ2 strain immunized mice and the control mice show obvious pathological lesions (figure 4).
5. Serum antibody level change results of delta cra inactivated vaccine immunized mice
After the mice are immunized for the first time, blood of tail veins of the mice in a delta cra immune group, a negative control group and a blank control group are collected every 7d, igG antibody levels in serum are measured, the serum is continuously detected for 119d, the dynamic change results of the antibodies are shown in figure 5, the IgG antibody levels in bodies of the mice immunized by delta cra inactivated vaccine reach the highest basically after 21d, the mice can be maintained for about 9 weeks, and the serum IgG antibodies of the mice in the blank control group are zero all the time.
6. Cross protection test of inactivated vaccine in chicken
In order to evaluate the cross protection property of the Δcra strain in the poultry body, pmQ muscle is selected for virus attack infection after the Δcra inactivated vaccine is immunized for 21d, and the survival condition is continuously observed for one week, as shown in fig. 6, the Δcra inactivated vaccine has the protection function on infection of avian origin type A Pasteurella multocida.
Finally, it should be noted that the above embodiments are only for illustrating the technical solution of the present invention and not for limiting the technical solution, and those skilled in the art should understand that modifications and equivalents may be made to the technical solution of the present invention without departing from the spirit and scope of the present invention, and all such modifications and equivalents are included in the scope of the claims.
Biological material sample preservation information
Biological material naming: pasteurella multocida PmCQ2Δcra (Pasteurella multocida PmCQ2Δcra)
Preservation unit name: china center for type culture Collection
Deposit unit address: university of Chinese Wuhan
Preservation date: 2022 9/20
Preservation number: cctccc No. M20221451.
Claims (8)
1. A strain of bovine Pasteurella multocida, characterized in that the strain is a strain of bovine Pasteurella multocida PmCQ2craThe gene deletion strain is preserved in China Center for Type Culture Collection (CCTCC) with the preservation number of M20221451.
2. The bovine-derived pasteurella multocida strain of claim 1, wherein said strain is selected from the group consisting ofcraIn the case of the gene-deleted strain,crathe amino acid sequence of the gene deletion part is SEQ ID NO.1.
3. The bovine origin pasteurella multocida strain of claim 1 or 2, characterized in that it has a cross-immune protective function and has the ability to cross-species infect poultry.
4. A pasteurella vaccine, characterized in that it is produced using a strain of pasteurella multocida of bovine origin a according to claim 1 or 2.
5. Use of a pasteurellosis vaccine according to claim 4, for immunization, to promote cross-immune protection of animals against infection by pasteurellosis of different serotypes and animal origin.
6. The use of a pasteurella vaccine according to claim 5, characterized in that the cross-protection is a cross-immune protection against a type a, B, F multocida infection of bovine origin.
7. The use of a pasteurella vaccine according to claim 5, characterized in that the cross-protection is a cross-immune protection against pasteurella multocida infection of porcine and rabbit origin.
8. The use of a pasteurella vaccine according to claim 5, characterized in that the cross-protection is a cross-immune protection against pasteurella multocida of avian origin, superior to pasteurella multocida vaccine of avian origin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211185443.3A CN116790456B (en) | 2022-09-27 | 2022-09-27 | Bovine origin A type Pasteurella multocida strain, vaccine and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211185443.3A CN116790456B (en) | 2022-09-27 | 2022-09-27 | Bovine origin A type Pasteurella multocida strain, vaccine and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116790456A true CN116790456A (en) | 2023-09-22 |
| CN116790456B CN116790456B (en) | 2024-04-30 |
Family
ID=88047164
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211185443.3A Active CN116790456B (en) | 2022-09-27 | 2022-09-27 | Bovine origin A type Pasteurella multocida strain, vaccine and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116790456B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1325731A (en) * | 2000-06-09 | 2001-12-12 | 阿克佐诺贝尔公司 | Living toxic-reduced bacteria as vaccine |
| KR20080060859A (en) * | 2006-12-27 | 2008-07-02 | 전남대학교산학협력단 | Avirulent attenuated strain of pasteurella multocida and live vaccine containing the same |
| US20080241192A1 (en) * | 2007-03-26 | 2008-10-02 | Wyeth | Vaccination against multiple serotypes of pasteurella multocida |
| CN113801812A (en) * | 2021-09-02 | 2021-12-17 | 华中农业大学 | Pasteurella multocida and application thereof |
| CN113855793A (en) * | 2021-10-19 | 2021-12-31 | 西南大学 | Application of bovine-derived A-type pasteurella multocida gene-deleted strain |
-
2022
- 2022-09-27 CN CN202211185443.3A patent/CN116790456B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1325731A (en) * | 2000-06-09 | 2001-12-12 | 阿克佐诺贝尔公司 | Living toxic-reduced bacteria as vaccine |
| KR20080060859A (en) * | 2006-12-27 | 2008-07-02 | 전남대학교산학협력단 | Avirulent attenuated strain of pasteurella multocida and live vaccine containing the same |
| US20080241192A1 (en) * | 2007-03-26 | 2008-10-02 | Wyeth | Vaccination against multiple serotypes of pasteurella multocida |
| CN113801812A (en) * | 2021-09-02 | 2021-12-17 | 华中农业大学 | Pasteurella multocida and application thereof |
| CN113855793A (en) * | 2021-10-19 | 2021-12-31 | 西南大学 | Application of bovine-derived A-type pasteurella multocida gene-deleted strain |
Non-Patent Citations (2)
| Title |
|---|
| ABUBAKAR MUSA AHMAD: "EFFORTS TOWARDS THE DEVELOPMENT OF RECOMBINANT VACCINES AGAINST PASTEURELLA MULTOCIDA", 《SCIENCE WORLD JOURNAL》, vol. 9, no. 2, 31 December 2014 (2014-12-31), pages 1 - 7 * |
| 李甜: "多杀性巴氏杆菌群体感应基因缺失株（ΔqseC及ΔqseCΔluxS）的构建及其生物学特性研究", 《中国知网硕士电子期刊》, no. 5, 15 May 2022 (2022-05-15), pages 1 - 67 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116790456B (en) | 2024-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112481154B (en) | Mycoplasma ovipneumoniae vaccine strain, vaccine composition prepared from vaccine strain and application of vaccine composition | |
| CN110699312B (en) | Brucella strain BI-1 gene deletion strain as well as construction method and application thereof | |
| CN106928373B (en) | Multi-epitope mucosal vaccine for mycoplasma hyopneumoniae | |
| CN116059333B (en) | Bovine origin A type Pasteurella multocida gene deletion strain and application thereof | |
| CN115851771B (en) | Salmonella typhi attenuated isolate strain without expressing Peg pili and application thereof | |
| CN110680912B (en) | H3N2 and H3N8 subtype canine influenza bivalent inactivated vaccine as well as preparation method and application thereof | |
| CN109609468B (en) | Six-gene-deleted porcine pseudorabies virus, porcine pseudorabies vaccine and preparation method thereof | |
| CN110201153B (en) | Triple inactivated vaccine for rabbit viral hemorrhagic disease, pasteurellosis and bordetella disease and preparation method thereof | |
| JP2718518B2 (en) | Mycoplasma vaccine | |
| CN107823639B (en) | Inactivated vaccine for bovine viral diarrhea virus and preparation method thereof | |
| CN108558998B (en) | Preparation and application of recombinant yeast preparation co-expressed by pig interleukin 4/6 and fused pig antibacterial peptide | |
| CN109810933A (en) | 2 type Streptococcus suis apuA gene knockout mutant strains of one kind and its application | |
| CN116790456B (en) | Bovine origin A type Pasteurella multocida strain, vaccine and application | |
| CN110016457B (en) | Rough brucella abortus for recombining echinococcus granulosus Eg95gene and vaccine production method thereof | |
| CN105154377B (en) | Recombinant salmonella pullorum, preparation method and application | |
| CN115850404A (en) | Recombinant erysipelothrix rhusiopathiae surface protection antigen A with tandem dominant epitopes and application thereof | |
| CN102321638B (en) | New porcine reproductive and respiratory syndrome virus ORF5 modified gene and application thereof | |
| CN115887631A (en) | Haemophilus parasuis and streptococcus suis combined vaccine | |
| CN113278575B (en) | Attenuated mutant strain of mycoplasma pneumoniae and application thereof | |
| CN115991749A (en) | Porcine infectious pleuropneumonia-porcine pasteurellosis bigeminal subunit vaccine | |
| CN112442473B (en) | Avian Escherichia coli vaccine strain | |
| CN109939225B (en) | Rough brucella abortus of recombinant chlamydia psittaci outer membrane protein MOMP gene and vaccine production method thereof | |
| CN112063596A (en) | Pigeon paramyxovirus type 1 PPMV-1/BJ-C strain and application thereof | |
| CN103421729B (en) | Gene recombined swine cholera salmonella choleraesuis vaccine for blue-ear disease and application thereof | |
| CN105524862A (en) | Salmonella pullorum spiC-rfaJ double-gene-knockout attenuated strain and DIVA vaccine application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |